카테고리 없음

Undifferentiated Pleomorphic Sarcoma Market Growth Analysis By DelveInsight

anjrawat 2021. 7. 1. 15:36

Undifferentiated Pleomorphic Sarcoma (UPS), previously known as malignant fibrous histiocytoma, is an aggressive sarcoma of soft tissues that can arise from any part of the body, clinically presenting as swelling, mass, pain, pathological fracture, and occasional systemic features. It is characterized by high local recurrence and significant metastasis. The most common sites of involvement include lower extremities (mainly thighs) followed by upper arms, retroperitoneum, viscera, head, and neck (in childhood).

 

Undifferentiated Pleomorphic Sarcoma Market Key Facts

  • A retrospective cohort analysis from 2001 to 2011 of the SEER study population (aged more than 65 years) with advanced STS, reported that undifferentiated Pleomorphic sarcoma (UPS) accounted for 15.3% of all STS in the United States (Parik et al., 2018).
  • Undifferentiated pleomorphic sarcoma (UPS) ranks the 4th most common soft tissue sarcoma with a slight male preponderance. The incidence has been evaluated to be close to 0.8−1 new case/100,000/year.
  • UPSs account for 10% of adult STSs and represent one of the most common STSs of older adults, with most occurring between the ages of 50 and 70 years. Pediatric UPSs are rare.
  • UPS is most commonly found in the lower limbs, upper limbs, and retroperitoneum. UPS accounts for 2.7–38% of the primary head and neck sarcomas.
  • Males are slightly more affected as compared to females in the case of Undifferentiated Pleomorphic Sarcoma.

DelveInsight's "Undifferentiated Pleomorphic Sarcoma Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the disease, historical and forecasted epidemiology, the pipeline insight as well as the Undifferentiated Pleomorphic Sarcoma market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. The report also covers emerging drugs, current treatment practices, Undifferentiated Pleomorphic Sarcoma market shares of the individual therapies, a detailed current Undifferentiated Pleomorphic Sarcoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the market. 

 

Undifferentiated Pleomorphic Sarcoma Market Growth

Among 7MM, the United States accounted for the highest market size of undifferentiated pleomorphic sarcoma (UPS) in comparison to EU5 and Japan. The Undifferentiated Pleomorphic Sarcoma market size is anticipated to increase during the study period owing to the rising healthcare expenditure, enhancement in the quality of patient care, and increasing adoption of new drugs in the 7MM.

 

The Undifferentiated Pleomorphic Sarcoma market analysis section of the report helps to understand the current and forecasted Undifferentiated Pleomorphic Sarcoma market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers. 

 

The report gives complete detail of Undifferentiated Pleomorphic Sarcoma market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

 

Companies all over the globe are persistently working toward the development of new treatment therapies for Undifferentiated Pleomorphic Sarcoma. The launch of the therapies are expected during the forecast period.

 

Some of the key Undifferentiated Pleomorphic Sarcoma Companies actively involved in the development of therapies include Merck, Genentech, MedImmune, AstraZeneca, Iovance Biotherapeutics, Covance Biotherapeutics, Tracon Pharmaceuticals, and others. Undifferentiated Pleomorphic Sarcoma Therapies covered in the report include LN-145, Durvalumab, Tremelimumab, Pembrolizumab, Bevacizumab, and many more. 

 

Undifferentiated Pleomorphic Sarcoma Epidemiology Segmentation

  • Incident Cases of Soft-tissue Sarcoma
  • Incident Cases of Undifferentiated Pleomorphic Sarcoma
  • Diagnosed and Treated Cases of Undifferentiated Pleomorphic Sarcoma

Undifferentiated Pleomorphic Sarcoma Epidemiology Forecast

The Undifferentiated Pleomorphic Sarcoma epidemiology section covers insights about historical and current Undifferentiated Pleomorphic Sarcoma patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan. It helps to recognize the causes of current and forecasted Undifferentiated Pleomorphic Sarcoma Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.  

 

For more details, visit: Undifferentiated Pleomorphic Sarcoma Market Growth